ENLVEnlivex TherapeuticsENLV info
$1.24info5.08%24h
Global rank27085
Market cap$23.06M
Change 7d3.33%
YTD Performance-56.64%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Enlivex Therapeutics (ENLV) Stock Overview

    Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

    ENLV Stock Information

    Symbol
    ENLV
    Address
    14 Einstein StreetNess Ziona, 7403618Israel
    Founded
    -
    Trading hours
    -
    Website
    https://www.enlivex.com
    Country
    🇮🇱 Israel
    Phone Number
    972 8 662 3301

    Enlivex Therapeutics (ENLV) Price Chart

    -
    Value:-

    Enlivex Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.24
    N/A
    Market Cap
    $23.06M
    N/A
    Shares Outstanding
    18.60M
    N/A
    Employees
    0
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org